UCB
The HEOR & HTA Manager leads HTA negotiations and CEA analysis for the Japanese market, optimizing drug pricing strategies from clinical development through post-launch. The role involves creating cost-effectiveness evaluation materials, managing HEOR projects, and collaborating with global teams and stakeholders to maximize product value for patients and healthcare providers. This position supports reimbursement and pricing strategies while monitoring policy changes and contributing to industry activities.
Headquarters
Brussels, Brussels, Belgium
Company Size
5001-10000 employees
Founded
1928
UCB a global biopharmaceutical leader focuses on creating valuable solutions that improve the lives of people living with neurological and autoimmune conditions
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for UCB.
UCB didn’t post a salary, so this is our estimate from similar listings.
Director, HEOR Product Lead - Remote
Diversity Employment
International HEOR & HTA Director, NS
Novartis
Senior Manager, HEOR (HTA, SLR, ITC)
Regeneron Pharmaceuticals
International HEOR & HTA Associate Director
Novartis
Global HEOR Strategy Lead
Denali Therapeutics
Senior Consultant/Manager HEOR (Health Economics & HTA)
IQVIA